Search hospitals

>

Colorado

>

Denver

Rose Medical Center

Claim this profile

Denver, Colorado 80220

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Lymphoma

Conducts research for Melanoma

293 reported clinical trials

3 medical researchers

Photo of Rose Medical Center in DenverPhoto of Rose Medical Center in DenverPhoto of Rose Medical Center in Denver

Summary

Rose Medical Center is a medical facility located in Denver, Colorado. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Lymphoma, Melanoma and other specialties. Rose Medical Center is involved with conducting 293 clinical trials across 405 conditions. There are 3 research doctors associated with this hospital, such as Nicholas DiBella, Andrew S. Kennedy, and Keren Sturtz.

Area of expertise

1

Breast Cancer

Global Leader

Rose Medical Center has run 58 trials for Breast Cancer. Some of their research focus areas include:

ER positive
Stage IV
HER2 negative
2

Lung Cancer

Global Leader

Rose Medical Center has run 45 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Rose Medical Center

Lung Cancer

Melanoma

Esophageal cancer

Cutaneous Melanoma

Bladder Cancer

Lymphoma

Breast Cancer

Prostate Cancer

Colorectal Cancer

Multiple Myeloma

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Rose Medical Center?